Collecting real-world information about EWS gene fusions and resulting peptides may be leveraged to help design future immunologic approaches including identifying in a more precise manner (e.g., with HLA binding assays, T-call and B-cell recognition assays) what constructs to include in personalized cancer vaccines. The gene discussed is EWSR1; the disease is cancer.